‘Year in’ type 2 diabetes: epidemiology, aetiology and treatment
Across
- 4. The _____ Investigators examined the relationship between the DPP-IV inhibitors/GLP-1 receptor agonists and heart failure.
- 6. In more affluent countries, recent studies demonstrate a ____ in all-cause mortality and the incidence of cardiovascular complications in patients with type 2 diabetes.
- 8. In the DEVOTE study, degludec was _________ to glargine in regard to severe hypoglycaemia in type 2 diabetic patients with high cardiovascular risk.
- 9. Reduced _______ adipose tissue storage capacity is a key determinant of insulin-resistance and that this link is mediated by specific and multiple genetic factors.
- 10. _______ reported a cardiovascular benefit for canagliflozin.
- 12. In the Devote study, degludec was non-inferior to ______ in relation to cardiovascular events.
Down
- 1. The ______trial reported that bariatric surgery plus intensive medical therapy was superior to the latter alone in improving glycaemic control, cardiovascular risk factors and quality of life after 5 years in moderate- and severely-obese patients with type 2 diabetes.
- 2. In the ________ study, liraglutide lowered cardiovascular death and non-fatal events in patients with type 2 diabetes.
- 3. In _______, semaglutide lowered cardiovascular death and non-fatal events in patients with type 2 diabetes.
- 5. Transplantation of cold-adapted ____ increases beige adipocytes in mice.
- 7. The _________ study demonstrates that empagliflozin reduces the risk of non-fatal myocardial infarction and cardiovascular death and slows the progression of diabetic kidney disease.
- 11. ______ examined the long-term effect of an intensified, multifactorial intervention on gained years of life.